Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07077902 · ClinicalTrials.gov registry record · Phase 2
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
A Phase 2 study of Hidradenitis Suppurativa, sponsored by Tulane University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 4
- Study locations
NCT07077902 is a Phase 2 study of Hidradenitis Suppurativa that is actively recruiting participants, run by Tulane University. The registered enrollment target is 10 participants, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT07077902, a Phase 2 study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by Tulane University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase 2a, open label study. As psoriasis and Hidradenitis Suppurativa (HS) share multiple inflammatory pathways, the investigators hypothesize that the use of topical roflumilast 0.3% foam is a safe and efficacious option as a monotherapy for patients with mild disease and as add-on therapy for maintenance and flares in patients with moderate to severe disease. The study will include correlative analysis to study gene expression profiling before and after therapy.
Conditions Studied
Interventions
- DRUG Topical roflumilast 0.3% foam
Study Locations (4)
Louisiana
- Lakeview Hospital - Covington
- Lakeside Hospital - New Orleans
- LCMC Multi-speciality Clinic - New Orleans
- University Medical Center - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-09-25 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07077902
The ClinicalTrials.gov registry entry for NCT07077902 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 598-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (98% lower). The listed sponsor is Tulane University, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which Topical roflumilast 0.3% foam is the first listed.
NCT07077902 reports 4 study locations spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT07077902 about?
NCT07077902 is a clinical study titled "A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa". This is a phase 2a, open label study. As psoriasis and Hidradenitis Suppurativa (HS) share multiple inflammatory pathways, the investigators hypothesize that the use of topical roflumilast 0.3% foam is a safe and efficacious option as a monotherapy for patients with mild disease and as add-on thera...
What is the current status of trial NCT07077902?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-09-25. Estimated completion is 2026-09.
What conditions does trial NCT07077902 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT07077902?
The interventions under investigation include: Topical roflumilast 0.3% foam (DRUG).
Who is sponsoring clinical trial NCT07077902?
This trial is sponsored by Tulane University, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07077902 being conducted?
This trial has 4 study locations across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.